Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HBV-ISS (Dynavax).

Joseph Jao-Yiu Sung1, Henry Lik-Yuen

  • 1Department of Medicine and Therapeutics, 9/F Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong, SAR, PR China. Josesung@cuhk.edu.hk

Current Opinion in Molecular Therapeutics
|April 14, 2006
PubMed
Summary

Dynavax is developing a novel hepatitis B vaccine, HBV-ISS (Heplisav), using virus antigens and an immunostimulatory DNA sequence adjuvant. This vaccine aims to prevent and treat hepatitis B virus infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling.

Cancer cell·2026
Same author

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.

Gut·2026
Same author

Risk-based screening programmes for cancer diagnosis: A systematic review with narrative synthesis.

Annals of the Academy of Medicine, Singapore·2025
Same author

A six-tiered framework for evaluating AI models from repeatability to replaceability.

Trends in biotechnology·2025
Same author

Multi-cohort analysis reveals colorectal cancer tumor location-associated fecal microbiota and their clinical impact.

Cell host & microbe·2025
Same author

Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge.
  • Current HBV vaccines exist, but advancements in adjuvant technology offer potential for improved efficacy.

Purpose of the Study:

  • To describe the development of HBV-ISS (Heplisav), a novel vaccine candidate for hepatitis B.
  • To highlight the components and mechanism of action of this new vaccine.

Main Methods:

  • Utilizing hepatitis B virus (HBV) antigens.
  • Incorporating Dynavax's immunostimulatory DNA sequence (ISS) adjuvant, specifically ISS-1018.
  • Leveraging ISS-1018's function as a Toll-like receptor 9 (TLR-9) agonist.

Main Results:

  • HBV-ISS (Heplisav) combines viral antigens with a potent immune-stimulating adjuvant.
  • The TLR-9 agonist adjuvant is designed to enhance the immune response against HBV.

Conclusions:

  • HBV-ISS (Heplisav) represents a promising vaccine strategy for the prevention and treatment of HBV infection.
  • The novel adjuvant technology may offer an advantage in combating hepatitis B.

Related Experiment Videos